Photopharmics
Salt Lake City, US · 2 known investors
PhotoPharmics develops Celeste, an investigational photo-neuromodulation device being evaluated in clinical trials for Parkinson's disease. The non-invasive, home-based device delivers light through the eyes to explore the role of retinal and circadian signaling pathways in addressing motor and non-motor symptoms of Parkinson's disease.
Deep TechHealthtechMedical Devices
Investors · 2
In the news
- Photopharmics closes $6 million to advance Parkinson’s devicelongevity.technology · 2025
- Photopharmics raises $6M for Parkinson's light therapy deviceparkinsonsnewstoday.com · 2025